News on Medial

CellCentric Raises $120M for Multiple Myeloma Drug; Genentech Pays $105M Upfront in $2B Orionis Cancer Deal | DeepNewz VC

deepnewz · 2m ago

Medial

CellCentric has successfully raised $120 million to support the development of its multiple myeloma drug. In a related pharmaceutical deal, Orionis Biosciences has entered a strategic partnership with Genentech, focusing on the discovery and development of a new class of cancer medicines known as molecular glues. This partnership includes an upfront payment of $105 million from Genentech, with the potential for additional payments totaling up to $2 billion.